Clinical Efficacy of Pulsed Radiofrequency Combined with Intravenous Lidocaine Infusion in the Treatment of Subacute Herpes Zoster Neuralgia

Table 3

Secondary outcome between the two groups of patients before and after surgery.

	PSQI		SAS		SDS		Tsba		IRTI
	Control	Treated	Control	Treated	Control	Treated	Control	Treated	Control	Treated
T0	16.35 ± 0.43	16.36 ± 0.37	55.39 ± 2.83	55.16 ± 2.31	52.42 ± 2.83	51.60 ± 2.31	4.46 ± 0.56	4.18 ± 0.59	35.68 ± 0.26	35.76 ± 0.33
T1	10.98 ± 0.36^a	9.08 ± 0.30^ab	48.35 ± 2.17^a	47.71 ± 3.12^ab	49.73 ± 2.17^a	47.57 ± 3.12^ab	1.71 ± 0.45^a	1.59 ± 0.49^a	35.14 ± 0.12^a	34.50 ± 0.11 ^ab
T2	10.74 ± 0.20^a	8.17 ± 0.30^ab	47.31 ± 2.37^a	47.94 ± 1.82^a	48.01 ± 2.37^a	47.01 ± 1.82^a	1.65 ± 0.48^a	1.31 ± 0.47^ab	35.15 ± 0.14^a	34.12 ± 0.10 ^ab
T3	9.85 ± 0.15^a	6.53 ± 0.24^ab	47.41 ± 2.54^a	44.93 ± 2.13^ab	47.34 ± 2.54^ab	44.94 ± 2.13^ab	1.46 ± 0.50^a	1.09 ± 0.29^ab	34.89 ± 0.14^a	34.13 ± 0.12^a
T4	8.62 ± 0.27^a	7.48 ± 0.19^ab	34.75 ± 3.54^a	30.10 ± 2.12^ab	34.66 ± 3.54^a	33.26 ± 2.12^a	1.81 ± 0.39^a	0.96 ± 0.17^ab	34.91 ± 0.13^a	35.30 ± 0.13^a
T5	8.54 ± 0.17^a	7.54 ± 0.23^ab	34.91 ± 2.48^a	28.89 ± 2.30^ab	34.87 ± 2.48^a	33.42 ± 2.30^a	1.56 ± 0.50^a	0.87 ± 0.33^ab	34.90 ± 0.11^a	35.31 ± 0.13^a

Comparison with T₀,^a; comparison with simultaneous point A group ^b